Print  |  Close

An Open-Label, Phase 2 Trial of Nanatinostat in Combination With Valganciclovir in Patients With Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas

Active: Yes
Cancer Type: Hematopoietic Malignancies
Non-Hodgkin Lymphoma
Unknown Primary
NCT ID: NCT05011058
Trial Phases: Phase II Protocol IDs: VT3996-202 (primary)
Eligibility: 18 Years and older, Male and Female Study Type: Treatment
Study Sponsor: Viracta Therapeutics, Inc.
NCI Full Details:


A Phase 2 study to evaluate the efficacy of nanatinostat in combination with
valganciclovir in patients with relapsed/refractory EBV-positive lymphomas


Patients with EBV-associated lymphomas have inferior outcomes with standard-of-care
therapies compared to those with EBV-negative disease. Nanatinostat is a selective class
I HDAC inhibitor which induces EBV lytic phase protein generation, activating
(val)ganciclovir to its cytotoxic form. This open-label, multicenter, multinational,
single-arm, Phase 2 basket study employs a Simon's 2-stage design to allow termination of
enrollment into cohorts where treatment appears futile, and will include the following
cohorts of patients with EBV+ relapsed/refractory lymphomas:

1. EBV+ diffuse large B-cell lymphoma (DLBCL, NOS)

2. Peripheral T-cell lymphoma (PTCL), including PTCL-NOS and AITL

3. Post-transplant lymphoproliferative disorder (PTLD)

4. EBV+ lymphoproliferative disorders other than the above, including Extranodal
NK/T-cell lymphoma (ENKTL)

Treatment Sites in Georgia

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.